间变性淋巴瘤激酶 (ALK) 是胰岛素受体超家族中的受体酪氨酸激酶,主要在脑中表达,与神经元发育和认知有关。ALK 催化 γ-磷酸基团从三磷酸腺苷 (ATP) 转移到底物蛋白上的酪氨酸残基。因此,它催化其底物蛋白上的酪氨酸残基磷酸化反应。蛋白质的磷酸化和去磷酸化是由不同酶(激酶和磷酸酶)催化的关键反应,它们在各种细胞功能中发挥关键作用。
ALK 基因激活参与多种人类癌症的致癌过程,如间变性大细胞淋巴瘤、肺癌、炎性肌纤维母细胞瘤和神经母细胞瘤,这是与其他致癌基因(NPM、EML4、TIM 等)融合或基因扩增、突变或蛋白质过表达的结果。ALK 是一种跨膜酪氨酸激酶受体,当配体与其胞外域结合时,会发生二聚化,随后胞内激酶域会发生自身磷酸化。当在癌症中被激活时,它代表特定抑制剂的靶点,例如克唑替尼、色瑞替尼、艾乐替尼等,这些抑制剂的使用已证明对 ALK 阳性非小细胞肺癌尤其有效。
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, is predominantly expressed in the brain and implicated in neuronal development and cognition. ALK catalyzes the transference of a gamma-phosphate group from adenosine triphosphate (ATP) to a tyrosine residue on a substrate protein. Therefore, it catalyzes a tyrosine residue phosphorylation reaction on its substrate proteins. The phosphorylation and dephosphorylation of proteins are critical reactions catalyzed by different enzymes (kinases and phosphatases), which play critical roles in various cellular functions.
ALK gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression. ALK is a transmembrane tyrosine kinase receptor that, upon ligand binding to its extracellular domain, undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. When activated in cancer it represents a target for specific inhibitors, such as Crizotinib, Ceritinib, Alectinib etc. which use has demonstrated significant effectiveness in ALK-positive non-small cell lung cancer particularly.
ALK5 ligand-1(a31 的 ALK5 配体)是间变性淋巴瘤激酶 ALK5 的配体,对 ALK5 的选择性高于 ALK4,可用于合成靶向 ALK5 的 PROTAC 降解剂,而 ALK5 PROTACs 可诱导依赖泛素-蛋白酶体系统的 ALK5 降解并发挥抗纤维化活性,因此 ALK5 ligand-1 可用于肺纤维化的研究。
ALK5 ligand-1-amine-C2-piperazine-C4-OH 是一种靶向 ALK5 的配体与 PROTAC Linker 的偶联物,可用于合成 PROTAC 降解剂 (a31),而 ALK5 PROTACs 可诱导依赖 UPS 的、相对于 ALK4 的选择性 ALK5 降解,因此该化合物可用于肺纤维化的研究。
Brigatinib A 是一种 GID4 连接酶配体,可用于合成 PROTAC BCR-ABL Degrader-2 (MS-V16311)。
Ceritinib-amide-C3-acid 是一种靶蛋白配体-连接子偶联物,包含蛋白配体 Ceritinib (MS-J67370) 和用于连接 E3 连接酶配体的连接子,可用于合成 TD-004 (MS-O39401)。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号